Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE OF REVIEW: This review aims to bring together recent developments relevant to the design of HIV-1 envelope glycoprotein-based immunogens to elicit broadly neutralizing antibodies (bNAbs). RECENT FINDINGS: The combined use of structural biology and deep sequencing of antigen-specific B-cell lineages has allowed cross-sectional and longitudinal views of antibody evolution towards broad and potent neutralization of HIV-1. Recent advances in molecular modelling allied with protein and glycoprotein engineering have fuelled the design of new-generation viral envelope glycoproteins (Env)-based antigens. SUMMARY: Although proof-of-principle for vaccine elicitation of bNAbs to HIV-1 is still lacking, many of the conceptual hurdles are being addressed.

Original publication

DOI

10.1097/COH.0000000000000054

Type

Journal article

Journal

Curr Opin HIV AIDS

Publication Date

05/2014

Volume

9

Pages

217 - 223

Keywords

Antibodies, Neutralizing, B-Lymphocytes, HIV Antibodies, HIV Envelope Protein gp120, HIV Infections, Humans